Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  by Froeschl, Sandra et al.
ORIGINAL ARTICLE
Outcomes of Second-Line Chemotherapy in Patients with
Relapsed Extensive Small Cell Lung Cancer
Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor Gallant, MSc,
and Scott A. Laurie, MD, FRCPC
Introduction: Extensive-disease small cell lung cancer (ED SCLC)
is characterized by initial chemosensitivity, followed inevitably by
relapse. The optimal role of additional chemotherapy at the time of
progression is controversial. We reviewed the experience of all
patients over a 5-year period with ED SCLC to describe outcomes of
second-line chemotherapy.
Methods: Records of all patients registered at The Ottawa Hospital
Regional Cancer Centre with ED SCLC were reviewed, and baseline
prognostic factors, chemotherapy delivered, and treatment outcomes
were extracted. Multivariate analyses were performed to determine
the effect of second-line chemotherapy on survival.
Results: Of 192 patients who completed first-line chemotherapy,
only 62 (32%) received second-line therapy; these patients were
younger and fitter, and lived longer from the time of relapse (5.2 vs.
1.5 months). Second-line therapy was an independent predictor of
survival. Benefit was observed in patients with relapse either before
or after 60 days from the completion of first-line therapy.
Conclusions: Second-line chemotherapy given at the time of relapse
of ED SCLC seems to be associated with prolongation of survival,
even in patients traditionally felt to have chemoresistant disease. The
majority of patients, however, do not receive second-line therapy
because of poor clinical status at relapse.
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Small cell lung cancer (SCLC) accounts for 15 to 18% ofall lung cancers,1 and is staged as either potentially cur-
able limited-disease (LD) or incurable extensive-disease
(ED). This aggressive cancer has a potential for early hema-
togenous spread, and therefore the majority of patients
present with ED. Palliative chemotherapy is the standard
treatment for ED SCLC, with partial and complete responses
seen in 70 and 10%, respectively.2,3 Nevertheless, despite
these high response rates to first-line chemotherapy, ED
SCLC frequently relapses quickly, and in recent clinical
trials, the median survival (MS) from the time of initiation of
therapy is only 8 to 10 months.4–6 Nevertheless, first-line che-
motherapy remains the essential component of treatment for ED
SCLC, as it improves survival over best supportive care.7
In North America, cisplatin and etoposide (EP) is the
standard first-line chemotherapy regimen used for treatment
of SCLC.8,9 In the elderly or those with contraindications,
cisplatin is frequently replaced by carboplatin. A relapse
within 2 to 3 months following completion of first-line
chemotherapy is thought likely to represent chemoresistant
disease, whereas a relapse beyond 3 months is considered to
indicate potentially chemosensitive disease. Those who
progress on first-line therapy (refractory disease) are thought
to have a particularly poor prognosis.
The treatment strategy for patients at the time of relapse
remains controversial. For those with chemosensitive disease,
options include re-treatment with the regimen used for first-line
therapy; cyclophosphamide-doxorubicin-vincristine (CAV); or
single-agent topotecan. In two small trials of only 15 and 37
patients, many of which initially presented with limited-stage
disease and had a very long progression-free interval, re-treat-
ment with the first-line regimen has been reported to lead to
responses in up to 67% of patients.10,11 In another trial that
enrolled only those who had relapsed more than 90 days from
their induction regimen, 211 patients with ED SCLC were
randomized to receive either CAV or intravenous topotecan.12
Outcomes were the same in both arms, with objective responses
observed in roughly 20%, and aMS from the start of second-line
therapy for 25 weeks. There are no prospective trials comparing
re-treatment with the induction regimen to an alternate second-
line strategy. Patients with chemoresistant or refractory disease
are routinely excluded from second-line trials, and the value of
additional chemotherapy in these patients is less clear. Our
objective therefore was to review outcomes of second-line che-
motherapy for ED SCLC in an unselected patient population, to
determine which patients with ED SCLC receive second-line
chemotherapy, and whether second-line chemotherapy offers
patients a benefit in terms of prolongation of survival.
PATIENTS AND METHODS
The Ottawa Hospital Regional Cancer Centre (TOHRCC)
is a comprehensive, university-affiliated cancer treatment
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facility that serves as the sole provider of oncologic care for
a population of 1.2 million. After approval by the research
ethics board of The Ottawa Hospital, the database of the
TOHRCC was searched to retrieve the charts of all patients
with a diagnosis of ED SCLC registered at the TOHRCC over
a 5-year period (January 1, 1999, to December 31, 2003). All
patients registered at the center who received at least one
cycle of first-line chemotherapy were included. Pathologic
confirmation of pure SCLC was required; mixed small cell
and non-small cell histologies were excluded. The extracted
data included demographics (sex, age, date of diagnosis,
smoking status), known baseline prognostic factors (Eastern
Cooperative Oncology Group [ECOG] performance status
[PS], weight loss, number and sites of metastatic disease, and
serum sodium [Na], lactate dehydrogenase [LDH], hemo-
globin [Hgb], platelets), first- and second-line treatment de-
tails (regimen, number of cycles, start and end dates), and
outcomes (response to treatment as documented by the treat-
ing physician, relapse, date of relapse, sites of relapse, sur-
vival status, and date of last follow-up or death). Because of
an excessive number of missing values, LDH was excluded
from the analyses to avoid case-wise deletions. Potential
prognostic factors, similar to those listed above, were also
extracted at the time of relapse. Patients who progressed on or
relapsed within 60 days of completion of first-line therapy
were classified as having chemoresistant disease.
Statistical Analysis
Outcome intervals were calculated from the date of initi-
ation of first-line therapy to the date of death for overall survival,
and from the date of completion of either first-line or second-line
chemotherapy to the date of first radiographic or clinical evi-
dence of progression or death for time to progression (TTP). 2
and analysis of variance tests evaluated differences between the
groups.13 Kaplan-Meier point estimate survival analyses were
used in evaluating the median TTP and overall survival.14
Survival differences between groups were analyzed with the log
rank statistics.15 Significant predictors of survival were demon-
strated with a Cox proportional hazards regression model, using
a stepwise selection procedure with a significance of p 0.2 for
a variable to stay in the model.16 The following variables
thought to have influenced survival from the time of relapse
were entered into a univariate analysis: age, gender, PS at the
time of relapse, sites of metastatic disease, response to first-line
therapy, disease sensitivity at relapse (chemoresistant vs. che-
mosensitive), whether the patient received second-line treat-
ment, Hgb, platelet level, and serum Na. All analyses were
performed using SPSS v 13 (Chicago, IL).
RESULTS
Patient Population
Between January 1999 and December 2003, 274 patients
with ED SCLC were registered at TOHRCC. Of these, 223
patients received first-line chemotherapy. The remaining 51
patients did not for the following reasons: patient refusal (n 
20); treated elsewhere (n  2); too unwell or died before
chemotherapy (n 29). Of the 223 included patients, 161 (72%)
patients received first-line treatment only, while 62 (28%) went
on to receive second-line chemotherapy. Figure 1 schematically
accounts for the patients included and excluded from the anal-
yses. A summary of the 223 patients is presented in Table 1
comparing the baseline characteristics of those patients who
received only first-line with those who received first-line and
second-line treatment. Patients who received second-line ther-
apy were significantly younger (64 vs. 69 years, p 0.003), and
tended to have a better PS than those who did not (p 0.06); the
groups were otherwise similar. There were no differences in the
median number of cycles of first-line chemotherapy patients in
either group received or in the regimen administered. The most
commonly prescribed first-line regimens were EP (52%) and
etoposide and carboplatin (ECb) (37%).
Response to First-Line Chemotherapy
For the 223 patients, the complete (CR) and partial
response (PR) rates (as determined by the treating physician)
FIGURE 1. Patient flow.
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were 7 and 71%, respectively. Stable disease was reported in
4%, while 14% had disease progression as their best response
to chemotherapy. There were 23 patients whose response to
chemotherapy could not be determined, either because of
death because of toxicity, or loss to follow-up. For these
patients, the median time from the initiation of treatment to
death was 15 days, with a range of 4 to 116 days.
The group of patients receiving second-line therapy had
a higher response rate than those who did not. Patients who
received only first-line had a 62% response rate (5% CR and
57% PR), whereas patients receiving first-line and second-
line treatment had a 94% response rate (11% CR and 84%
PR) to their first-line treatment (p  0.002).
Relapse Following First-Line
Of the 223 treated patients, 192 patients relapsed; this
includes the 32 patients who were refractory and progressed on
first-line therapy. Thirty-one patients died while receiving first-
line therapy, because of either progressive disease or treatment-
related toxicity, while an additional 23 patients were lost to
follow-up during or after completion of first line therapy. All 23
of these latter patients are known to have died, presumably of
SCLC, but their date of relapse is not known. These patients
were therefore unavailable for consideration of second-line che-
motherapy, and are excluded from all subsequent analyses.
Thus, there are 169 patients who are known to have relapsed
after completion of first-line therapy and who could potentially
have received second-line treatment, and these patients form the
cohort for the remaining analyses. The median TTP for all 169
patients from the completion of first-line chemotherapy was 2.1
month. The median TTP following first-line treatment in those
who did go on to receive second-line therapy was longer than
those who did not (2.9 vs. 1.7 months), but this difference was
not statistically significant (p  0.14).
Second-Line Chemotherapy
Of the 169 relapsed patients, 62 (37% of the 169 patients
who relapsed and could have received additional therapy; 28%
of the original 223 treated patients) went on to receive second-
line therapy. Table 2 presents the characteristics of the patients
at the time of relapse following their first-line chemotherapy,
comparing those who received first-line to those who received
first-line and second-line. Forty-one of the 62 patients who
received additional chemotherapy relapsed more than 60 days
from the completion of first-line therapy; 37% of these chemo-
sensitive patients were re-treated with the same regimen. Of the
21 chemoresistant patients who relapsed within 60 days of the
completion of their first-line therapy, 85% were treated with a
different regimen. The most commonly administered second-
line regimen was CAV. As expected, physician-determined
response to therapy was lower in the chemoresistant group
(24%) compared with the chemosensitive group (46%). A low
serum sodium and a poorer PS both tended to be associated with
a worse outcome in those patients receiving second-line therapy.
TABLE 1. Baseline Patient Characteristics
First Line Only
(n  161)
Second Line
(n  62)
All Patients
(n  223)
Age (range) 69 (42–89) 64 (35–84) 67 (35–89)
Female 38% 43% 40%
ECOG PS
0 7% 13% 9%
1 46% 54% 49%
2 45% 32% 41%
Unknown 2% 1% 1%
Site of metastases
Brain 18% 16% 17%
Liver 51% 58% 53%
Bone 40% 39% 40%
Adrenal 17% 19% 18%
Skin 1% 2% 1%
Chest 6% 8% 7%
Other 15% 27% 18%
Median Na (mmol/L) 137 139 137
Median LDH (IU) 440 428 435
Median Hgb (g/dL) 131 132 131
Median Plts (109) 280 281 281
First line chemo
EP 54% 48% 52%
ECb 38% 34% 37%
CAV 2% 3% 3%
TOPO 1% 0% 1%
OTHER 5% 15% 7%
Median number of cycles
first line
4 (1–8) 6 (1–9) 5 (1–9)
ECOG PS, Eastern Cooperative Oncology Group performance status; EP, etoposide
and cisplatin; ECb, etoposide and carboplatin; CAV, cyclophosphamide-doxorubicin-
vincristine; TOPO, topotecan. TABLE 2. Characteristics of Patients at Relapse (n  169)
First-Line Only
(n  107)
First-Line and Second-Line
(n  62)
Age (median) 67 64
Female 37% 44%
ECOG PS
0–1 22% 60%
2 78% 40%
Median Na (mmol/L) 138 137
Median LDH (IU) 420 626
Median Hgb (g/dL) 119 121
Median Plts (109) 232 248
First-line Response
CR 7.5% 11.3%
PR 72.9% 83.9%
SD 6.5% 0.0%
Progression 7.5% 4.8%
Unknown 5.6% 0.0%
Site of relapse
Brain 37.4% 22.6%
Liver 13.1% 32.3%
Bone 20.6% 19.4%
Adrenal 3.7% 3.2%
Skin 0.9% 1.6%
ECOG PS, Eastern Cooperative Oncology Group performance status.
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Survival
The overall MS from diagnosis for all 223 patients was
7.8 months (95% confidence interval [CI], 7.0–9.0); patients
receiving only first-line chemotherapy had a MS of 6.2
months (95% CI, 4.9–7.1 month) from the time of diagnosis,
while patients who received second-line chemotherapy had a
MS of 11.4 months (95% CI, 10.3–15.1 month) (p  0.001).
For the 169 patients for whom second-line therapy was
available, the MS from the time of relapse following first-line
chemotherapy was 1.5 months (95% CI, 1.2–1.9 months) in
the patient group that received only first-line chemotherapy;
it was 5.2 months (95% CI, 3.8–6.5 months) in the group that
received second-line chemotherapy (p  0.0001) (Figure 2).
Patients with a chemosensitive relapse receiving second-line
therapy had a MS of 6.3 (95% CI, 4.6–8.2) months, com-
pared with 2.0 (95% CI, 1.4–3.0) months for chemosensitive
patients who did not receive such therapy (p  0.0001)
(Figure 3). Patients with a chemoresistant relapse receiving
second-line therapy had a MS of 3.7 (95% CI, 3.0–5.7)
months, compared with 1.3 (95% CI, 0.9–1.8) months for
patients with chemoresistant disease who did not receive
second-line therapy (p  0.002) (Figure 4).
Univariate and Cox Regression Analysis of
Predictors of Survival Following Relapse
This analysis included the 169 patients who relapsed
following, or progressed on, first-line treatment, and were avail-
able for second-line therapy. Table 3 lists the results of the
univariate analysis, identifying ECOG PS 2, use of second-
line chemotherapy, Na and Hgb as factors that significantly
predict survival in patients following first-line treatment. In a
multivariate Cox regression analysis, independent predictors of
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survival following first-line chemotherapy were ECOG PS 2,
a serum sodium of 130 mmol/L, age at diagnosis and receipt
of second-line treatment. Gender, platelets, response to first-line
therapy, chemosensitivity of relapse, and sites of relapse did not
predict survival following relapse (Table 3).
DISCUSSION
Although widely accepted that second-line chemother-
apy offers benefit to some patients with relapsed ED SCLC,
at the time we initiated this review there was little evidence
from clinical trials that additional therapy at the time of
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FIGURE 4. Median survival from re-
lapse following first-line chemother-
apy: chemoresistant patients.
TABLE 3. Univariate and Cox Regression of Predictors of Survival Following Relapse
Predictor Variable
Univariate Analysis Multivariate Analysisa
HR 95% CI p HR 95% CI p
Age 0.986 0.97–1.00 0.07 0.97 0.95–0.99 0.00015
Female gender 0.84 0.61–1.15 0.28
ECOG PS
0–1 1 1
2 1.6 1.2–2.2 0.0039 2.2 1.5–3.6 0.0004
Treatment received
1st line only 1 1
1st  2nd line 0.47 0.33–0.65 0.0001 0.29 0.19–0.45 0.0001
Serum sodium (130 vs. 130) 2.37 1.51–3.71 0.0001 2.29 1.45–3.61 0.0004
Hemoglobin (100 vs. 100) 1.53 0.89–2.65 0.12
Platelets (continuous variable) 1 0.99–1.002 0.87
Sites of Disease (Absence vs. Presence)
Brain 0.77 0.55–1.09 0.14
Liver 0.94 0.64–1.4 0.94
Adrenal 0.86 0.38–1.95 0.72
Bone 1.29 0.88–1.89 0.19
Skin 1.12 0.28–4.55 0.87
Chemosensitive vs. chemoresistant relapse 0.60 0.44–0.82 0.0012
Response to first-line therapy
(CR/PR versus SD/PD/unknown)
0.43 0.28–0.64 0.0001
ECOG PS, Eastern Cooperative Oncology Group performance status; CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
a The multivariate analysis included only those variable where significance 0.2 in the univariate analysis.
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relapse resulted in a prolongation of survival.17 Chemother-
apy use in this setting was justifiable, particularly in patients
with chemosensitive disease, based upon the reasonable num-
ber of objective responses observed, and the suggestion that
second-line therapy might be associated with an improvement
of quality of life.12 A review of the Southwest Oncology
Group (SWOG) SCLC database suggested that, at relapse, the
only predictors of improved outcome were a normal LDH and
treatment with EP, if this was not the regimen used as
first-line therapy.18 Spiro et al. randomized 610 patients (414
with ED) to receive either four or eight cycles of first-line
therapy with cyclophosphamide-vincristine-etoposide, with a
further randomization to receive second-line chemotherapy
with methotrexate-doxorubicin at the time of disease progres-
sion.19 This study found that survival in the subgroup with
ED was inferior if only four cycles of first-line therapy were
administered, but that either eight cycles of first-line therapy
or four cycles of first-line therapy followed by additional
therapy at relapse were equivalent with respect to survival.
The relevance of this study, and of the SWOG retrospective
review, to current practice, in which EP is the standard
first-line therapy, is unclear.
The first study to compare second-line therapy with
best supportive care (BSC) has only recently been pub-
lished.20 This trial randomized 141 patients with relapsed
SCLC who were ineligible to receive further intravenous
chemotherapy to treatment with oral topotecan or BSC alone.
Patients were stratified by treatment-free interval (45–60 days
vs. more than 60 days); the median treatment-free interval in
both arms was 90 days. Patients receiving topotecan had an
increased median survival (26 vs. 14 weeks, p  0.01), and
this benefit was observed in both the chemosensitive and
chemoresistant subgroups. In addition, patients receiving to-
potecan had a slower rate of deterioration of quality of life.
Three-quarters of enrolled patients received platinum or eto-
poside or both as their first-line therapy; an analysis of
relative benefit of oral topotecan by type of first-line therapy
received was not provided.
Our review suggests that additional chemotherapy at
the time of relapse may be associated with an increase in
median survival of 4 months, independent of other potential
prognostic factors. Retrospective analyses of this type are
subject to selection bias related to the nonrandom assignment
of treatment to individual patients. Multivariable regression
analyses can correct for the measurable, tangible factors
(such as age, gender, PS, laboratory values), but cannot
account for the intangible factors that go into a physician’s
treatment decision-making, or for missing measurable factors
(such as our inability to include LDH in the multivariable
regression model because of missing data). There are clear
differences in patient characteristics between those who did
and those who did not receive second-line therapy (Table
2). Nevertheless, our analysis has shown that the use of
second-line chemotherapy predicted for improved survival
independent of age, gender, performance status, number
and sites of metastatic disease, laboratory parameters and
response to first-line therapy. The magnitude of this sur-
vival benefit is similar to that observed in the randomized
trial discussed above. Other factors known to be prognostic
in SCLC, such as ECOG PS, were detected in the current
analysis, and the overall median survival of the 223 pa-
tients was 7.8 months, comparable to that seen in clinical
trials of first-line therapy for ED SCLC, suggesting that
our patient population is typical of the general population
of patients with SCLC. Thus, despite the limitations in-
herent in retrospective reviews, the current report provides
support for the claim that chemotherapy at relapse of
SCLC improves survival, although we cannot exclude the
possibility that selection bias accounts for some, or all, of
this benefit.
Retrospective reviews of institutional experience are
useful for quality assurance, hypothesis generation, and iden-
tification of issues related to clinical trials in the disease in
question. In this review, we found that those patients with
chemoresistant disease who received second-line therapy had
a longer survival compared with those with chemoresistant
disease who were not treated. This challenges the notion that
chemoresistant patients do not benefit from second-line ther-
apy. Although fewer objective responses are observed in this
population, chemotherapy may still alter the natural history
by stabilizing disease and / or slowing the rate of progression.
In the trial of topotecan versus BSC in relapsed SCLC, a
similar increase in median survival was observed in both
chemosensitive and chemoresistant patients.20 Patients with
chemoresistant disease should therefore be considered for
second-line chemotherapy, and should not be routinely ex-
cluded from clinical trials.
Less than one-third of all patients presenting with ED
SCLC in the current series went on to receive second-line
therapy. In general, those who did not were older and less fit,
and more likely to have had a poorer response to first-line
therapy. De Jong et al. compared characteristics of patients
who received third-line chemotherapy for SCLC and also
found that patients who received third-line chemotherapy
were younger, had a better PS and had a better response to
first-line treatment.21 Thus, there is likely some bias among
oncologists against treating certain types of patients with ED
SCLC at relapse, while some patients may have refused in the
absence of data suggesting a survival benefit to therapy in this
situation. Although some chemoresistant or refractory pa-
tients may not have been offered additional therapy based on
the assumption that they would not benefit, even if second-
line therapy is now accepted as standard, the data still
indicate that only a minority of patients with ED SCLC will
go on to receive it. At the time of relapse, most patients were
likely felt to be too unwell to tolerate further therapy, and this
is borne out by the very short median survival. Closer and
more frequent surveillance of patients at the completion of
induction therapy may permit a resumption of therapy while
the patients are still medically fit; given that the median TTP
from first-line therapy is only 2 months, it may be prudent to
assess these patients at least monthly. Nevertheless, priority
should be directed instead to improving outcomes of first-line
therapy, as this will benefit a far larger proportion of the
population with ED SCLC.
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